MORGAN STANLEY PLC/CALL/NOVARTIS N/105/0.1/20.06.25 Stock

Warrant

DE000ME2ZRM1

Real-time Bid/Ask 11:20:02 2024-07-02 EDT
0.3 EUR / 0.32 EUR +3.33% Intraday chart for MORGAN STANLEY PLC/CALL/NOVARTIS N/105/0.1/20.06.25
1 month+30.43%
3 months+98.68%
Date Price Change
24-07-02 0.32 +6.67%
24-07-01 0.3 +7.14%
24-06-28 0.28 -3.45%
24-06-27 0.29 -6.45%
24-06-26 0.31 +3.33%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 08:45 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVARTIS AG
Issuer Morgan Stanley
WKN ME2ZRM
ISINDE000ME2ZRM1
Date issued 2023-11-02
Strike 105 CHF
Maturity 2025-06-20 (353 Days)
Parity 10 : 1
Emission price 0.24
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.35
Lowest since issue 0.123
Delta0.3x
Omega 9.527
Premium12.45x
Gearing31.43x
Moneyness 0.9151
Difference Strike 8.575 CHF
Difference Strike %+8.17%
Spread 0.01
Spread %3.13%
Theoretical value 0.3150
Implied Volatility 18.31 %
Total Loss Probability 75.55 %
Intrinsic value 0.000000
Present value 0.3150
Break even 108.06 €
Theta-0.01x
Vega0.03x
Rho0.02x

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
-
More about the company

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Novartis AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
107 USD
Average target price
110.3 USD
Spread / Average Target
+3.05%
Consensus